|
| View previous topic :: View next topic |
| Author |
Message |
ChefLinda
Moderator
Joined: 20 Sep 2006
Posts: 24165
Location: Boston
|
 Posted: Mon Jun 06, 2022 3:46 am Post subject: NYT: A Cancer Trial’s Unexpected Result: Remission in Every Patient |
|
|
This is incredible. I hope they can repeat it with other forms of cancer in other trials. Would be huge.
NYT: A Cancer Trial’s Unexpected Result: Remission in Every Patient
| Quote: | It was a small trial, just 18 rectal cancer patients, every one of whom took the same drug.
But the results were astonishing. The cancer vanished in every single patient, undetectable by physical exam, endoscopy, PET scans or M.R.I. scans.
Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by the drug company GlaxoSmithKline, said he knew of no other study in which a treatment completely obliterated a cancer in every patient.
“I believe this is the first time this has happened in the history of cancer,” Dr. Diaz said.
Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, who was not involved with the study, said he also thought this was a first.
A complete remission in every single patient is “unheard-of,” he said.
These rectal cancer patients had faced grueling treatments — chemotherapy, radiation and, most likely, life-altering surgery that could result in bowel, urinary and sexual dysfunction. Some would need colostomy bags.
They entered the study thinking that, when it was over, they would have to undergo those procedures because no one really expected their tumors to disappear.
But they got a surprise: No further treatment was necessary.
“There were a lot of happy tears,” said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper, which was presented Sunday at the annual meeting of the American Society of Clinical Oncology.
Another surprise, Dr. Venook added, was that none of the patients had clinically significant complications. |
|
|
| Back to top |
|
 |
leor_77
Franchise Player
Joined: 23 Mar 2012
Posts: 21920
|
| Posted: Mon Jun 06, 2022 9:08 pm Post subject: |
|
|
I believe the bigger news of the weekend was actually AstraZeneca's breast cancer drug, "Enhertu." Apparently, the results of the study were so good, the crowd at the conference gave them a long standing ovation. What I think was/is so good was that this was given to late stage breast cancer patients, where there are few effective treatments.
"in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death by 49%, whilst improving overall survival by 36% compared to chemotherapy when given as third-line treatment.
That translated to an extra six months of life – from 16.8 months to 23.4 months – a result that AZ said is potentially redefining treatment for approximately half of all patients with breast cancer." |
|
| Back to top |
|
|
focus
Star Player
Joined: 23 May 2012
Posts: 2526
|
| Posted: Tue Jun 07, 2022 11:33 am Post subject: |
|
|
| Actual good news! (for a change) |
|
| Back to top |
|
|
|
|
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum
|
|
